Zacks Investment Research upgraded shares of OpGen Inc (NASDAQ:OPGN) from a hold rating to a buy rating in a report released on Saturday. The brokerage currently has $1.50 target price on the stock.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Separately, Rodman & Renshaw set a $3.30 target price on OpGen and gave the company a buy rating in a research note on Wednesday, August 10th.

OpGen (NASDAQ:OPGN) opened at 1.3399 on Friday. The firm’s market capitalization is $29.03 million. The company has a 50-day moving average price of $1.32 and a 200 day moving average price of $1.58. OpGen has a 1-year low of $0.87 and a 1-year high of $4.65.

OpGen (NASDAQ:OPGN) last announced its earnings results on Monday, October 24th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.04. Analysts expect that OpGen will post ($1.17) earnings per share for the current fiscal year.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

5 Day Chart for NASDAQ:OPGN

Receive News & Stock Ratings for OpGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc and related stocks with our FREE daily email newsletter.